Baxter Falls After Goldman Sachs Downgrade By

By Sam Boughedda — Baxter International Inc (NYSE:) fell 3.7% on Monday after the stock was downgraded to sell from neutral by Goldman Sachs (NYSE:).

In a note to investors, analyst Amit Hazan, who also lowered the price target to $77 from $88, said that while a U.S. Covid recovery is developing, other macro factors have intensified, resulting in headwinds for the MedTech sector. 

He added that the company is more exposed to macro headwinds than its peers, and it is the least exposed to the developing Covid recovery tailwinds.

“We continue to see pockets of concern for the base business which in the aggregate further reduce the probability of top line upside,” stated the analyst. 

Baxter shares have fallen 11.61% in 2022.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.